1. Executive Overview
Gaudium IVF and Women Health Limited, founded in 2015, is a leading healthcare provider focused on IVF and reproductive health services in India. Established by Dr. Manika Khanna, the company has grown from a single clinic to a pan-India network using a hub-and-spoke model. It offers a wide range of fertility treatments, from basic care to advanced IVF solutions.
The company operates across 30+ locations, including 7 major hubs and multiple spoke centers, with presence in key regions like Delhi NCR, Maharashtra, and Karnataka. It also serves international patients from over 40 countries. Gaudium IVF stands out for its asset-light model and strong clinical performance, maintaining a success rate of around 58%. With the IVF market in India growing rapidly, the company is well-positioned for future expansion.
2. Business Model and Revenue Streams
Gaudium IVF utilizes an asset-light, Hub-and-Spoke operational model designed for rapid scalability and high resource optimization.
- Hub Centers: These are centers of excellence located in Tier-1 cities that perform advanced procedures such as OPU (Ovum Pick-Up), ET (Embryo Transfer), and cryopreservation.
- Spoke Centers: These centers act as the primary patient touchpoints for consultations and preliminary care, feeding complex cases into the major Hubs.
- Revenue Segments: The company's primary income is derived from IVF Treatments, supplemented by Hospital services (mother and child care) and Pharmacy sales through its subsidiary, Gaudium International Private Limited.
- Pricing & Payment: The company offers flexible treatment packages that vary based on case complexity, allowing for lump-sum payments or installments to improve affordability.
Financial Performance & Revenue Breakdown (₹ in Lakhs)
| Services Offered | Sept 30, 2025 (Stub) | % of Revenue | Fiscal 2025 | % of Revenue | Fiscal 2024 | % of Revenue |
|---|---|---|---|---|---|---|
| IVF Treatment | 3,393.34 | 68.55% | 5,554.38 | 78.54% | 4,222.43 | 88.17% |
| Pharmacy | 1,427.99 | 28.85% | 1,172.24 | 16.57% | 195.20 | 4.08% |
| Hospital | 128.55 | 2.60% | 345.78 | 4.89% | 371.39 | 7.75% |
| Total | 4,949.88 | 100.00% | 7,072.40 | 100.00% | 4,789.01 | 100.00% |
Key Industry-Specific Operating Metrics
| Particulars | Sept 30, 2025 | Fiscal 2025 | Fiscal 2024 | Fiscal 2023 |
|---|---|---|---|---|
| Total Cycles (OPU+ET) | 1,824 | 3,476 | 3,711 | 3,512 |
| Success Rate (%) | 58.74% | 58.23% | 58.03% | 57.01% |
| Avg. Revenue Per Patient (₹ Lakhs) | 2.58 | 3.55 | 1.89 | 3.44 |
| Total OPDs | 3,859 | 8,145 | 7,208 |
3. Products and Service Portfolio
The company offers a 360-degree suite of fertility and reproductive health services.
- Primary Fertility Treatments: Includes In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), and Intrauterine Insemination (IUI).
- Specialized Male Infertility Care: Advanced techniques like Testicular Sperm Aspiration (TESA) and Intracytoplasmic Morphologically Selected Sperm Injection (IMSI).
- Emerging Technology - GAAT: The Gaudium Advanced Analysis and Treatment (GAAT) module is a proprietary genome-sequencing process used to enhance success rates for high-risk patients.
- Fertility Preservation: Cryopreservation services (vitrification) for egg, sperm, and embryo freezing.
- Ancillary Health Services: High-risk pregnancy management, laparoscopic surgeries, and fertility wellness programs.
Operational Infrastructure by Center (Hubs)
| Center Location | State | ART Level | No. of Beds | IVF Facility |
|---|---|---|---|---|
| Janakpuri | Delhi | Level-2 | 15 | Yes |
| Mumbai | Maharashtra | Level-2 | 9 | Yes |
| Bengaluru | Karnataka | Level-2 | 7 | Yes |
| Srinagar | J&K | Level-2 | 7 | Yes |
| Patna | Bihar | Level-2 | 5 | Yes |
| Ludhiana | Punjab | Level-2 | 5 | Yes |
| Greater Kailash | Delhi | Level-1 | 3 |
4. Key Business Strengths
- Patient Centric Approach with dedicated counselors providing transparency and emotional support throughout the fertility journey.
- Expert Leadership Team led by Dr. Manika Khanna, a specialist with over 20 years of experience in complex infertility cases.
- Advanced Technological Integration utilizing next-generation labs, INTEGRA Ti for ICSI, and proprietary GAAT genome sequencing.
- Asset-Light Scalability through a refined Hub-and-Spoke model that minimizes capital expenditure for new market entries.
- Strong Regional Dominance with established central hubs in high-demand markets like Delhi NCR, Mumbai, and Bengaluru.
- Consistent Clinical Outcomes maintaining a high success rate of over 58% even as the volume of patients increases.
5. Future Growth Strategy
- Geographic Expansion of the Hub-and-Spoke model into underserved Tier-2 and Tier-3 Indian cities to capture untapped demand.
- Enhanced Digital Acquisition through targeted SEO, PPC, and social media marketing to build brand awareness globally.
- Proprietary Innovation by fully operationalizing the GAAT module to lead the market in genome-based personalized IVF.
- International Patient Growth by leveraging the London collaboration and expanding outreach in the Middle East and Africa.
- Capacity Optimization by centralizing advanced procedures at Hubs while increasing the volume of routine care at Spoke centers.
- Focus on Egg Freezing to cater to the growing trend of women opting for fertility preservation due to evolving life goals.
Delete Comment?
Are you sure you want to delete this comment? This action cannot be undone.
Discussion
Join the discussion!
Log In to CommentNo comments yet. Be the first to share your thoughts!